drugset / Trial / NCT00820417
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
Phase 1
Completed
63 enrolled
Harrison Clinical Research
AstraZeneca · collabMerck KGaA, Darmstadt, Germany · collab
Non-randomizedOpen-label
Summary
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR. Primary objective is the determination of the maximum tolerated dose (MTD) and recommended dose (RD) of the combination of intravenous Cetuximab and oral Gefitinib.
Timeline
- Start
- 2004-06
- Primary completion
- 2007-09
- Completion
- 2008-05